A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States

Drug and Alcohol Dependence

Volumn 57, Issue 1, 1999, Pages 7-22

  Cicero, Theodore J ^a   Adams, Edgar H ^b   Geller, Anne ^c   Inciardi, James A ^d   Muñoz, Alvaro ^e   Schnoll, Sidney H ^f   Senay, Edward C ^g   Woody, George E ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gordon S Black Corporation   (United States)

^c Columbia Univ Coll Phys Surgs ^*  (United States)

^d UNIVERSITY OF DELAWARE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Controlled Substances Act; Drug abuse; Drug dependence; Postmarketing surveillance; Tramadol HCl; Ultram

Indexed keywords

TRAMADOL;

ARTICLE; DRUG ABUSE; DRUG MARKETING; GEOGRAPHIC AND GEOLOGICAL PHENOMENA; HUMAN; INFORMATION PROCESSING; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ANALGESICS, OPIOID; HUMANS; PRESCRIPTIONS, DRUG; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS; TRAMADOL; UNITED STATES;

EID: 0032824204     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(99)00041-1     Document Type: Article

References (41)

1. Agar, M.H., 1980. The Professional Stranger: An Informal Introduction to Ethnography. Academic Press, Orlando.
2. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC.
3. Arend, L., Arnim, B., Nussen, J., Scheele, J., Flohe, L., 1978. Tramadol und Pentazocin im klinischen Doppelblind-Crossover-Vergleich. Arzneim. Forsch. 28, 199-208.
4. Breitbart, W., Rosenfeld, B.D., Passik, S.D., 1996. The undertreatment of pain in ambulatory AIDS patients. Pain 65, 239-249.
5. Brewer, T., Colditz, G.A., 1999. Postmarketing surveillance and adverse drug reactions. J. Am. Med. Assoc. 281, 824-829.
6. Cleeland, C.S., Gonin, R., Hatfield, A.., 1994. Pain and its treatment in outpatient with metastatic cancer. New Engl. J. Med. 330, 592-596.
7. Everitt, B., 1997. Craving cocaine cues: cognitive neuroscience meets drug addiction research. Trends Cogn. Neurosci. 1, 198-199.
8. Faich, G.A., 1986. Adverse-drug-reaction monitoring. New Engl. J. Med. 314, 1589-1592.
9. Foley, K., 1985. The treatment of cancer pain. New Eng. J. Med. 313, 84-95.
10. Frederichs, E., Felgenhauser, E., Joagschaap, P., Osterloh, G., 1978. Pharmacological investigations on analgesia and the development of dependence and tolerance with Tramadol, a strongly acting analgesia. Arzneim Forsch Drug Res. 28, 122-132.
11. Frink, M.Ch., Hennies, H.-H., Englberger, W., Haurand, M., Wilffert, B., 1996. Influence of Tramadol on neurotransmitter systems of the rat brain. Arzneim.-Forsch. 46 (11), 1029-1036.
12. Gardner, E., 1997. Brain reward mechanisms. In: Lowinson, J., Luis, P., Millman, R., Langrod, J. (Eds.), Substance Abuse. Williams and Wilkens.
13. Gilbert, P.L., Harris, M.J., McAdams, L.A., Jeste, D.V., 1995. Neuroleptic withdrawal in schizophrenic patients. Arch. Gen. Psychiatry 52, 173-188.
14. Johnson, S.M., Fleming, W.W., 1989. Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol. Rev. 41, 435-488.
15. Joranson, D., Gilson, A., 1994. Controlled substances, medical practice and the law. In: Schwartz, H.I. (Ed.), Psychiatric Practice Under Fire. American Psychiatric Press, Washington, DC, pp. 173-194.
16. Joranson, D.E., Cleeland, C.S., Weissman, D.E., Gilson, A.M., 1992. Opioids for chronic cancer and non-cancer pain: a survey of state medical board members. Fed. Bull. 79, 15-49.
17. Kelsey, J.L., Whittmore, A.S, Evans, A.S., Thompson, W.D., 1996. Methods in Observational Epidemiology. Oxford University Press, Oxford, England.
18. Kessler, D.A., 1993. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. J. Am. Med. Assoc. 269, 2765-2768.
19. Keup, W., 1993. Missbrauchsmuster bei abhangigkeit von alkohol, medikamenten und drogen: Fruhwarnsystem-daten für die bundesrepublik Duetschland 1976-1990. Lambertus, Freiburg im Breisgau.
20. Koob, G.F., Bloom, F.E., 1998. Cellular and molecular mechanisms of drug dependence. Science 242, 715-723.
21. Lai, J., Ma, S.-W., Porreca, F., Raffa, R.B., 1996. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur. J. Pharamcol. 316, 369-372.
22. Lejoyeux, M., Ades, J., 1997. Antidepressant discontinuation: a review of the literature. J. Clin. Psychatry 58 (Suppl 7), 11-15.
23. Murano, T., Yamamoto, E., Endo, N., Okada, N., Massuda, Y, Yano, I., 1978. Studies of dependence on Tramadol in rats. Arzneim Forsch. (Drug Res.) 28, 125-158.
24. Nutt, D., 1997. The neurochemistry of addiction. Hum. Psychopharm. 12, S53-S58.
25. Perry, S., Heindrich, G., 1982. Management of pain during debridement: a survey of U.S. burn units. Pain 13, 267-280.
26. Piazza-Hepp, T.D., Kennedy, D.L., 1995. Reporting of adverse events to Medwatch. Am. J. Health Syst. Pharm. 2, 1436-1439.
27. Portenoy, R.K., 1992. Inadequate outcome of cancer pain treatment: influences on patient and clinician behavior. In: Patt, R.B. (Ed.), Problems in Cancer Pain Management. JB Lippincott, New York, pp. 119-128.
28. Porter, J., Jick, H., 1980. Addiction rare in patients treated with narcotics. New Eng. J. Med. 302, 123.
29. Preston, K.L., Jasinski, D.R., Testa, M., 1991. Abuse potential and pharmacological comparison of Tramadol and morphine. Drug Alcohol Depend. 27, 7-18.
30. Raffa, R.B., Friderichs, E., Reiman, W., Shank, R.P., Codd, E.E., Vaught, J.L., 1992. Opioid and nonopioid components independently contribute to the mechanism of action of Tramadol, an 'atypical' opioid analgesic. J. Pharmacol. Exp. Ther. 260, 275-285.
31. Richter, W., Barth, H., Flohe, L., Giertz, H., 1985. Clinical investigation of the development of dependence during oral therapy with Tramadol. Arzneimittelforsch. (Drug Res.) 35, 1742-1744.
32. Richter, W., Flohe, L., Giertz, H., 1980. Clinical evaluation of dependence-liability of Tramadol. Naunyn Schmeidebergs Arch. Pharmacol. 313, 62.
33. Sigler, K.A., Guersney, B.G., Ingrim, N.B., 1984. Effect of a triplicate prescription law on prescribing of Schedule II drugs. Am. J. Hosp. Pharm. 41, 108-111.
34. Temple, R., 1999. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. J. Am. Med. Assoc. 281, 841-844.
35. Villarreal, J.E., Seevers, M.H., 1968 Evaluation of new compounds for morphine-like physician dependence in the rhesus monkey. Paper presented at a meeting of the National Academy of Sciences-National Research Council Committee on Problems of Drug Dependence, 30th Meeting, pp. 1-15.
36. Ward, S.E., Goldberg, N., Miller-McCauley, V., 1993. Patient barriers to management of cancer pain. Pain 52, 319-324.
37. Weintraub, M., Singh, S., Byrne, L., Maharaj, K., Guttmacher, L., 1991. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. J. Am. Med. Assoc. 266, 2392-2397.
38. Weissman, D.E., Joranson, D.E., Hopwood, M.B., 1991. Wisconsin physician's knowledge and attitudes about opioid analgesic regulations. Wisconsin Med. J., December.
39. Wikler, A., 1980. Opioid Dependence. Plenum, New York.
40. Yanagata, T., 1978. Drug dependence potential of 1-methesyphenyl-2-dimethylamimethyl-eyelohean-1-ol hydrochloride 'Tramadol' tested in monkeys. Arzneim. Forsch. (Drug Res.) 28, 158-163.
41. Yesalisy, C.E., Vicary, J.R., Buckley, W.E., Strait, A.L., Katz, D.L., Wright, J.E., 1990. Indications of psychological dependence among anabolic-androgenic abusers. In: Lin, G., Erinoff, L. (Eds.), Anabolic Steroid Abuse. National Institute on Drug Abuse, Rockville MD, pp. 196-214.